CHIKV Capsid
Escherichia Coli.
Protein is >90% pure as determined by SDS-PAGE.
Description
Recombinant Chikungunya Full length capsid protein containing 220 amino acids produced in E.coli having a molecular weight of 25kDa.
Product Specs
Chikungunya, a viral infection transmitted to humans through mosquito bites (Aedes albopictus and Aedes aegypti), is characterized by fever and joint pain. The virus can also infect animals like monkeys, birds, and rodents. After an incubation period of 2-4 days, individuals experience a sudden onset of fever, lasting for 2-7 days. Joint pains, a hallmark of the disease, can persist for weeks, months, or even years. While generally non-fatal, chikungunya has a mortality rate of approximately 1 in 1,000 cases. The virus, belonging to the alphavirus genus, possesses a single-stranded RNA genome that encodes viral proteins. These proteins assemble to form new viral particles, allowing the virus to replicate and spread within the host.
This product consists of the Chikungunya virus capsid protein, produced in a laboratory setting using E. coli bacteria. The protein encompasses the full length of the native capsid protein, comprising 220 amino acids, and has a molecular weight of 25kDa.
This solution has been sterilized through filtration and contains phosphate-buffered saline (PBS) at a concentration of 1x and potassium carbonate (K2CO3) at a concentration of 25mM.
For short-term storage (up to one week), CHIKV Capsid can be kept at 4°C. For long-term storage, it is recommended to store the protein below -18°C to ensure its stability. Avoid repeated freezing and thawing of the protein solution.
The purity of the CHIKV Capsid protein in this product is greater than 90%, as determined by SDS-PAGE analysis, a technique used to separate and analyze proteins based on their size.
Escherichia Coli.
Purified by proprietary chromatographic technique.
Product Science Overview
Chikungunya virus (CHIKV) is an arthropod-borne virus belonging to the genus Alphavirus in the Togaviridae family. It was first isolated in 1952 in Tanzania and has since caused numerous outbreaks in Africa, Asia, and the Americas . The virus is primarily transmitted to humans through the bites of infected Aedes mosquitoes, particularly Aedes aegypti and Aedes albopictus .
The capsid protein (CP) of CHIKV plays a crucial role in the virus’s life cycle. It is involved in the assembly of the viral particle and packaging of the viral RNA. The CP is produced as part of a polyprotein, which undergoes autoproteolytic cleavage to release the mature capsid protein . The monomeric CP is approximately 30 kDa in size and contains nuclear localization signals (NLS) and nuclear export signals (NES), allowing it to shuttle between the cytoplasm and the nucleus .
Recombinant technology has enabled the production of CHIKV capsid protein in various expression systems. This recombinant protein is used in research to study the virus’s structure, function, and interactions with host cells. It is also employed in the development of diagnostic tools and potential vaccines .
- Diagnostic Tools: Recombinant CHIKV capsid protein can be used to develop highly specific and sensitive diagnostic assays. These assays can detect CHIKV infections in clinical samples, aiding in the early diagnosis and management of the disease .
- Vaccine Development: The recombinant capsid protein is a potential candidate for vaccine development. It can be used to elicit an immune response in the host, providing protection against CHIKV infection .
- Research: The recombinant protein is valuable in studying the molecular mechanisms of CHIKV infection. It helps researchers understand how the virus interacts with host cells and evades the immune system .
